A new, powerful Citizen Portal experience is ready. Switch now

Senate consolidates PBM reforms into single measure; committee rolls in related bills

January 26, 2026 | 2026 Legislature VA, Virginia


This article was created by AI summarizing key points discussed. AI makes mistakes, so for full details and context, please refer to the video of the full meeting. Please report any errors so we can fix them. Report an error »

Senate consolidates PBM reforms into single measure; committee rolls in related bills
Several PBM reform proposals were discussed in a large panel that included Senator Rouse's pass-through pricing bill, Senator Ross's rebate-focused proposals and an administration-sponsored PBM reform package. Supporters—community pharmacies, independent pharmacists and pharmacy associations—urged pass-through pricing, limits on spread pricing, and that rebates be used for patient cost-sharing or plan savings. The Virginia Community Pharmacy Association and local pharmacy groups said PBM contracting practices have driven closures and created 'pharmacy deserts.'

Opponents (PBM trade groups and some payers) urged caution, citing contract complexity and potential downstream effects on premiums and plan design. Doug Gray of the Virginia Association of Health Plans said plans remain chief PBM customers and emphasized the need to preserve contracting flexibility while addressing unfair practices.

Committee actions: Senators moved to adopt substitutes, reconsider earlier committee votes and roll SB 410 and SB 413 into SB 669; the committee approved a motion to roll the bills together and reported SB 669 as amended to Finance for further consideration. The consolidated substitute includes pass-through pricing, rebate definitions and transitional timelines to allow carriers and PBMs to reconfigure systems.

Implications: The roll-in creates a single legislative vehicle to address PBM transparency, rebate pass-through and spread-pricing bans. Sponsors said passage would help preserve local pharmacy access and potentially reduce drug costs; opponents warned of complicated market impacts and urged additional negotiation.

View the Full Meeting & All Its Details

This article offers just a summary. Unlock complete video, transcripts, and insights as a Founder Member.

Watch full, unedited meeting videos
Search every word spoken in unlimited transcripts
AI summaries & real-time alerts (all government levels)
Permanent access to expanding government content
Access Full Meeting

30-day money-back guarantee